Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.
Iovance Biotherapeutics, Inc. develops and commercializes novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Company news commonly addresses Amtagvi, described by Iovance as the first FDA-approved T cell therapy for a solid tumor indication, Proleukin, lifileucel, and pipeline work across solid tumor cancers.
Recurring updates include clinical data, regulatory disclosures, operating and financial results, corporate presentations, material agreements, and governance matters. Iovance also reports Nasdaq inducement equity grants under its Amended and Restated 2021 Inducement Plan as part of its public-company compensation disclosures.
On May 26, 2022, Iovance Biotherapeutics reported clinical results from its C-144-01 study for advanced melanoma patients. In Cohort 4 (n=87), the objective response rate (ORR) was 29% with three complete responses and 22 partial responses, demonstrating the potential of lifileucel therapy in heavily pre-treated patients. Median duration of response for Cohort 4 was 10.4 months. A Biologics License Application (BLA) for lifileucel is planned for submission in August 2022. The company emphasizes the significance of these results as a new treatment option for patients with unmet medical needs.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced the grant of inducement stock options for 146,700 shares to 17 new non-executive employees on May 19, 2022. These awards fall under Iovance's 2021 Inducement Plan, which allows for equity awards to new hires. Each option has an exercise price of $14.95, the closing price on the date of grant, and will vest over three years, contingent upon continued employment. This initiative aims to strengthen talent retention as Iovance advances its innovative T cell-based cancer immunotherapies.
Iovance Biotherapeutics (NASDAQ: IOVA) reported its Q1 2022 financial results, showing a cash position of $516.0 million, sufficient to fund operations into 2024. The company anticipates a BLA submission for its lead product lifileucel in metastatic melanoma by August 2022. Key highlights include ongoing patient enrollment for TIL therapies and FDA feedback on potency assays. However, Iovance reported a net loss of $91.6 million in Q1 2022, increasing from $75.4 million in Q1 2021, and significant R&D and administrative expense growth.
Iovance Biotherapeutics (NASDAQ: IOVA) announced the presentation of translational data for lifileucel, targeting metastatic melanoma, at the 2022 ASCO Annual Meeting from June 3-7, 2022. The study focuses on tumor mutational burden in patients with different prior treatments with immune checkpoint inhibitors. The abstract, titled 'Tumor mutational burden in immune checkpoint inhibitor-naïve and -experienced patients treated with lifileucel,' will be featured on June 6, 2022, during the Melanoma/Skin Cancers session. Lifileucel is a promising TIL cell therapy aiming for FDA approval as a one-time treatment for solid tumors.
Iovance Biotherapeutics (NASDAQ: IOVA) announced it will report its Q1 2022 financial results on May 5, 2022. A conference call will follow at 4:30 p.m. ET for management to discuss results and provide corporate updates. The company is focused on pioneering T cell-based cancer therapies, particularly its lead candidate lifileucel for metastatic melanoma, aiming for it to be the first approved one-time cell therapy for solid tumors. Iovance highlights its commitment to innovation in cancer treatment.
Iovance Biotherapeutics, a late-stage biotechnology firm specializing in T cell-based cancer immunotherapies, announced its participation in the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit. The presentation featuring senior leadership will take place on April 26, 2022, at 1:30 p.m. ET. This event aims to showcase advancements in tumor infiltrating lymphocyte (TIL) therapies, with the company's lead candidate, lifileucel, being a potential first approved one-time cell therapy for solid tumors. The webcast will be accessible for live and archived viewing.
Iovance Biotherapeutics has granted inducement stock options for 323,675 shares to 34 new non-executive employees under its 2021 Inducement Plan. Each option has an exercise price of $16.07 and vests over three years, promoting long-term employee retention. The plan aligns with Nasdaq rules and aims to enhance the company's workforce as it develops T cell-based cancer therapies, including lifileucel for metastatic melanoma. Iovance's focus on innovative cell therapies highlights its commitment to improving cancer treatment.
Iovance Biotherapeutics announced positive FDA feedback on April 1, 2022, regarding its potency assay matrix for the upcoming Biologics License Application (BLA) for lifileucel, a treatment for metastatic melanoma. With this feedback, Iovance plans to request a pre-BLA meeting in July 2022 and aims to submit the BLA by August 2022. In addition, the company will initiate a Phase III study of lifileucel combined with pembrolizumab, demonstrating a 67% overall response rate in prior trials. The FDA granted Fast Track Designation for this combination due to its potential advantages.
Iovance Biotherapeutics announced its participation in key healthcare conferences in March 2022. The schedule includes:
- Oppenheimer Healthcare Conference: Fireside Chat on March 16 at 12:40 p.m. ET
- Barclays Global Healthcare Conference: Fireside Chat on March 17 at 10:45 a.m. ET
Live and archived webcasts will be available on Iovance's investor calendar. The company is focused on pioneering T cell-based cancer immunotherapies, particularly lifileucel for metastatic melanoma.
Iovance Biotherapeutics (NASDAQ: IOVA) announced on March 14, 2022, the approval of inducement stock options and restricted stock units covering 667,725 shares to nineteen new non-executive employees. These awards were granted under the 2021 Inducement Plan, which complies with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $12.38, and vesting occurs over three years. This initiative aims to attract talent to enhance Iovance's development of T cell-based cancer therapies, particularly its lead candidate, lifileucel, for metastatic melanoma.